{"id":"W4387114848","doi":"10.3324/haematol.2023.283557","title":"Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study","year":2023,"lang":"en","type":"article","venue":"Haematologica","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital","funders":"National Cancer Institute; Pharmacyclics; Genentech; F. Hoffmann-La Roche; Incyte; H. Lundbeck A/S; BeiGene; CSL Behring; AstraZeneca; MorphoSys; Celgene; Gilead Sciences; Teva Pharmaceutical Industries; Servier; TG Therapeutics; Amgen","keywords":"Bendamustine; Medicine; Obinutuzumab; Follicular lymphoma; Internal medicine; Tolerability; Rituximab; Adverse effect; Phases of clinical research; Gastroenterology; Lymphoma; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00335111,0.001490138,0.002735879,0.0004419465,0.0003988065,0.001255397,0.001161355,0.001281489,0.003010894],"category_scores_gemma":[0.00120078,0.0007918198,0.001958006,0.000553512,0.0009098059,0.0009228869,0.0004372127,0.002958607,0.0009277036],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001174474,"about_ca_system_score_gemma":0.002350158,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001061633,"about_ca_topic_score_gemma":0.002149204,"domain_scores_codex":[0.9990312,0.000529761,0.00006062522,0.0001526755,0.00008391498,0.00014186],"domain_scores_gemma":[0.998948,0.000141301,0.0001649706,0.0001367099,0.00008086903,0.0005282096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7799641,0.09008218,0.004065969,0.001263101,0.002256721,0.0002538724,0.0003474733,0.00160566,0.03497874,0.0003286043,0.003118804,0.08173487],"study_design_scores_gemma":[0.7167279,0.2726383,0.004624631,0.00005804194,0.0008712637,0.0001843971,0.00004775465,0.0005252669,0.001433905,0.0001489034,0.002717725,0.00002191655],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9847436,0.005086371,0.0007168094,0.0005388901,0.0001740218,0.004655706,0.001496419,0.00008954816,0.002498693],"genre_scores_gemma":[0.979954,0.004892983,0.002374349,0.001713752,0.0003865324,0.005076889,0.003107764,0.00004808338,0.002445577],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00335111,"threshold_uncertainty_score":0.01772255,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04273158087623399,"score_gpt":0.328386806788105,"score_spread":0.285655225911871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}